Merek dagang preparat lubiprostone.
|This article needs additional citations for verification. (April 2014) (Learn how and when to remove this template message)|
|ATC code||A06AX03 (WHO)|
|Metabolism||Extensive, CYP not involved|
|Biological half-life||Unknown (lubiprostone)
0.9–1.4 hours (main metabolite)
|Excretion||Renal (60%) and fecal (30%)|
|Chemical and physical data|
|Molar mass||390.462 g/mol|
|3D model (Jmol)||Interactive image|
|(what is this?)|
Lubiprostone (rINN, marketed under the trade name Amitiza among others) is a medication used in the management of chronic idiopathic constipation, predominantly irritable bowel syndrome-associated constipation in women and opioid-induced constipation.
It was initially approved by the U.S. Food and Drug Administration (FDA) in 2006. It is very expensive as of 2012.